Newport Beach, CA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation (“Bimergen” or the “Company”) (NYSE American: BESS, BESSWS), a utility-scale battery energy storage systems (BESS) asset owner, project developer, and independent power provider, today announced the pricing of an underwritten public offering of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and one accompanying warrant per common stock or Pre-Funded Warrant, at a public offering price of $4.00, fo ...

Energy Services of America Corporation Announces Pricing of $20.0 Million Public Offering of Common Stock [Accessibility Statement] Skip NavigationHUNTINGTON, W.Va., Feb. 19, 2026 /PRNewswire/ -- Energy Services of America Corporation (the "Company"), today announced the pricing of an underwritten public offering of 1,740,000 shares of its common stock at a price to the public of $11.50 per share. The Company also granted the underwriter a 30-day option to purchase up to an additional 261,000 shares of comm ...

Energy Services of America Corporation Announces Proposed Public Offering of Common Stock [Accessibility Statement] Skip NavigationHUNTINGTON, W.Va., Feb. 18, 2026 /PRNewswire/ -- Energy Services of America Corporation (the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company also expects to grant the underwriter a 30-day option to purchase additional shares of common stock of the Company in an amount of up to 15% of the numb ...

Core Viewpoint - Eupraxia Pharmaceuticals Inc. has filed a preliminary prospectus supplement for a proposed public offering of common shares to advance its clinical-stage biotechnology initiatives, particularly focusing on its proprietary Diffusphere™ technology for drug delivery [1][4]. Group 1: Offering Details - The company plans to offer common shares and may grant underwriters a 30-day option to purchase an additional 15% of the shares offered [2]. - The final terms of the offering will be determined at the time of pricing, and the completion of the offering is subject to customary closing conditions, including necessary approvals from the Toronto Stock Exchange and Nasdaq [2]. - Cantor and LifeSci Capital are acting as joint book-running managers, with Bloom Burton as a co-manager for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily support the advancement of EP-104GI for Eosinophilic Esophagitis, including ongoing preclinical studies and Phase 2 clinical trials, as well as preparations for a Phase 3 trial [4]. - Additional funds will be allocated to expand clinical studies for EP-104GI in other gastrointestinal indications and to support research and development of new pipeline candidates [4]. - The company also plans to use a portion of the proceeds for general corporate purposes, including employee salaries, working capital, and expanding its intellectual property portfolio [4]. Group 3: Company Overview - Eupraxia Pharmaceuticals is focused on developing locally delivered, extended-release products aimed at addressing significant unmet medical needs [7]. - The company's proprietary Diffusphere™ technology is designed to facilitate targeted drug delivery of both existing and novel drugs [7].

Core Viewpoint - Cineverse Corp. has announced a public offering of 1,500,000 shares of its Class A common stock at a price of $2.00 per share, aiming to raise approximately $3.0 million in gross proceeds before expenses [1]. Group 1: Offering Details - The public offering price is set at $2.00 per share, with a total of 1,500,000 shares being offered [1]. - Cineverse has granted the underwriter a 30-day option to purchase an additional 225,000 shares at the same public offering price [1]. - The offering is expected to close on February 17, 2026, pending customary closing conditions [1]. Group 2: Company Background - Cineverse is described as an innovative and independent entertainment technology company and studio, focusing on developing and investing in technology and content for the industry [1]. - The company operates Matchpoint®, a tech ecosystem powered by AI, designed to enhance content preparation, distribution, monetization, and performance across various platforms [1]. - Cineverse distributes over 71,000 premium films, series, and podcasts, and collaborates with leading brands to connect with valued audiences [1].

Core Viewpoint - OKYO Pharma Limited has announced a public offering of 10,815,000 ordinary shares at a price of $1.85 per share, aiming to raise approximately $20 million before expenses and discounts [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be around $20 million, with the potential to increase to approximately $23 million if the underwriter fully exercises its option to purchase additional shares [2]. - The offering is managed solely by Piper Sandler & Co., and is expected to close around February 17, 2026, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for clinical development of product candidates, general corporate purposes, and working capital [2]. Group 3: Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with shares traded on the Nasdaq Capital Market [6]. - The company has recently completed a successful Phase 2 trial of its lead drug, urcosimod, for NCP and plans to initiate a Phase 2b/3 study involving approximately 150 subjects in the first half of the year [6].

Core Viewpoint - Coherus Oncology, Inc. has announced a public offering of 28,600,000 shares of common stock at a price of $1.75 per share, aiming to raise approximately $50.1 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering price is set at $1.75 per share, with gross proceeds expected to be around $50.1 million before underwriting discounts and commissions [1]. - The company has granted underwriters a 30-day option to purchase an additional 4,290,000 shares at the public offering price [1]. - The offering is anticipated to close on or about February 17, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - Coherus plans to utilize the net proceeds from the offering to support the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of its product candidates, and for working capital and other general corporate purposes [2]. Group 3: Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes mid-stage clinical candidates targeting various cancers [5]. - The company's strategy focuses on growing sales of LOQTORZI in R/M nasopharyngeal carcinoma and advancing new indications in combination with its pipeline candidates and partners [5]. Group 4: Pipeline Information - Coherus' pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [6]. - Tagmokitug, a selective anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors, while Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [6].

Core Viewpoint - Cineverse Corp. has announced a proposed underwritten public offering of its Class A common stock, with the intention to grant the underwriter a 30-day option to purchase an additional 15% of the shares offered, subject to market conditions [1] Company Overview - Cineverse is described as an innovative and independent entertainment technology company and studio, focusing on developing and investing in technology and content that shapes the future of the industry [1] - The company operates Matchpoint®, a tech ecosystem powered by AI, designed to prepare, distribute, monetize, and continuously improve content across various platforms [1] - Cineverse distributes over 71,000 premium films, series, and podcasts across theatrical, home entertainment, and streaming platforms, and operates numerous digital properties catering to passionate fandoms globally [1] Offering Details - The offering is being underwritten by The Benchmark Company, LLC, and a shelf registration statement relating to the shares was previously filed with the SEC, becoming effective on January 25, 2024 [1] - The offering will be conducted through a written prospectus and prospectus supplement, which will be filed with the SEC and made available on their website [1]

$30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cashOffering led by Nantahala Capital, with participation of healthcare-dedicated funds, including Broadfin Holdings, and participation from existing shareholder, Glen Taylor, and members of the Company's board of directors and managementNet proceeds extend anticipated cash runway into second half of 2027, beyond expected PMA submission; if milestone- ...

Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases [5] - The company is listed on the Nasdaq Capital Market and is dedicated to discovering and developing novel molecules for treating ocular diseases [5] Offering Details - The company announced an underwritten public offering of its ordinary shares, with all shares to be sold by the company [1] - The underwriter, Piper Sandler & Co., will have a 30-day option to purchase up to an additional 15% of the shares sold at the public offering price [1][2] - The net proceeds from the offering will primarily be used for clinical development of product candidates, general corporate purposes, and working capital [2] Clinical Development - OKYO recently completed a successful Phase 2 trial of its flagship drug, urcosimod, in patients with NCP [5] - The company plans to initiate a Phase 2b/3 multiple-dose study of urcosimod, targeting approximately 150 subjects in the first half of the year [5] Regulatory Information - The securities are being offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3] - A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC and is available on their website [3]